This company has been acquired
Reata Pharmaceuticals Management
Management criteria checks 4/4
Reata Pharmaceuticals' CEO is J. Huff, appointed in Jan 2002, has a tenure of 21.67 years. total yearly compensation is $1.11M, comprised of 57.5% salary and 42.5% bonuses, including company stock and options. directly owns 0.81% of the company’s shares, worth $53.34M. The average tenure of the management team and the board of directors is 3.9 years and 4.8 years respectively.
Key information
J. Huff
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 57.50% |
| CEO tenure | 21.7yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$88m |
| Mar 31 2023 | n/a | n/a | -US$354m |
| Dec 31 2022 | US$1m | US$636k | -US$312m |
| Sep 30 2022 | n/a | n/a | -US$312m |
| Jun 30 2022 | n/a | n/a | -US$305m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$4m | US$636k | -US$297m |
| Sep 30 2021 | n/a | n/a | -US$278m |
| Jun 30 2021 | n/a | n/a | -US$271m |
| Mar 31 2021 | n/a | n/a | -US$266m |
| Dec 31 2020 | US$6m | US$636k | -US$248m |
| Sep 30 2020 | n/a | n/a | -US$369m |
| Jun 30 2020 | n/a | n/a | -US$343m |
| Mar 31 2020 | n/a | n/a | -US$310m |
| Dec 31 2019 | US$6m | US$579k | -US$290m |
| Sep 30 2019 | n/a | n/a | -US$129m |
| Jun 30 2019 | n/a | n/a | -US$120m |
| Mar 31 2019 | n/a | n/a | -US$114m |
| Dec 31 2018 | US$935k | US$534k | -US$81m |
| Sep 30 2018 | n/a | n/a | -US$72m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$36m |
| Dec 31 2017 | US$5m | US$514k | -US$48m |
| Sep 30 2017 | n/a | n/a | -US$35m |
| Jun 30 2017 | n/a | n/a | -US$24m |
| Mar 31 2017 | n/a | n/a | -US$13m |
| Dec 31 2016 | US$5m | US$450k | -US$6m |
Compensation vs Market: J.'s total compensation ($USD1.11M) is below average for companies of similar size in the US market ($USD8.17M).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
CEO
J. Huff (69 yo)
Mr. J. Warren Huff has been the Chief Executive Officer of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) and has been its Chairman since 2002 and serves as its Secretary since May 2023. He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 21.7yrs | US$1.11m | 0.81% $ 53.3m | |
| COO, CFO & President | 4.1yrs | US$4.00m | 0.020% $ 1.3m | |
| Executive VP and Chief Legal & Compliance Officer | 8.4yrs | US$2.86m | 0.031% $ 2.1m | |
| Executive VP & Chief Innovation Officer | no data | US$2.93m | 0.41% $ 26.9m | |
| Executive VP & Chief Commercial Officer | 7yrs | US$2.74m | 0.093% $ 6.1m | |
| Senior VP & Chief Accounting Officer | 1.8yrs | no data | 0.025% $ 1.7m | |
| Senior VP & Chief Scientific Officer | 3.7yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 4.4yrs | no data | no data | |
| Chief Medical Officer & Senior VP | 3.2yrs | no data | 0.013% $ 869.4k | |
| VP & Chief Healthcare Compliance Officer | 3.2yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | no data | no data | 0.075% $ 4.9m | |
| Executive VP and Chief Research & Development Officer | less than a year | no data | no data |
Experienced Management: RETA's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 21.7yrs | US$1.11m | 0.81% $ 53.3m | |
| Independent Director | 3.1yrs | US$353.43k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$349.91k | 6.72% $ 441.1m | |
| Lead Independent Director | 18.8yrs | US$391.34k | 0.96% $ 62.7m | |
| Independent Director | 6.5yrs | US$381.87k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$575.12k | 0.016% $ 1.1m | |
| Independent Director | 2.4yrs | US$344.94k | 0.010% $ 659.9k | |
| Independent Director | 2.4yrs | US$361.34k | 0.014% $ 900.3k |
Experienced Board: RETA's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/27 16:40 |
| End of Day Share Price | 2023/09/25 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Reata Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Dae Gon Ha | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |